Revenues

Revenues by product and by geographic area

We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold principally in Europe. Revenues were as follows (in millions):



	Three months ended June 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel^®	1,252		50		1,302		1,411		55		1,466
Neulasta^®	948		152		1,100		937		150		1,087
Prolia^®	396		214		610		326		179		505
Aranesp^®	241		231		472		288		247		535
Sensipar^® / Mimpara^®	330		90		420		342		85		427
XGEVA^®	339		113		452		292		103		395
EPOGEN^®	250		—		250		292		—		292
Other products	611		462		1,073		498		369		867
Total product sales⁽¹⁾	$	4,367	$	1,312	$	5,679	$	4,386	$	1,188	$	5,574
Other revenues					380						236
Total revenues⁽²⁾					$	6,059					$	5,810



	Six months ended June 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel^®	2,302		105		2,407		2,529		118		2,647
Neulasta^®	1,957		298		2,255		1,985		312		2,297
Prolia^®	716		388		1,104		605		325		930
Aranesp^®	466		460		926		566		480		1,046
Sensipar^® / Mimpara^®	739		178		917		679		169		848
XGEVA^®	671		226		897		590		207		797
EPOGEN^®	494		—		494		562		—		562
Other products	1,169		853		2,022		965		681		1,646
Total product sales⁽¹⁾	$	8,514	$	2,508	$	11,022	$	8,481	$	2,292	$	10,773
Other revenues					591						501
Total revenues⁽²⁾					$	11,613					$	11,274

^____________


⁽¹⁾	Total product sales includes $20 million related to hedging losses and $33 million related to hedging gains for the three months ended June 30, 2018 and 2017, respectively. Total product sales includes $54 million related to hedging losses and $90 million related to hedging gains for the six months ended June 30, 2018 and 2017, respectively.


⁽²⁾	Prior-period amounts are not adjusted under the modified-retrospective method of adoption.

Financing and payment

Our payment terms vary by types and locations of customers and the products or services offered. Payment terms differ by jurisdiction and customer, but payment is generally required in a term ranging from 30 to 120 days from date of shipment or satisfaction of the performance obligation.

For certain products or services and certain customer types, we may require payment before products are delivered or services are rendered to customers.

Optional exemptions

We do not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for the services performed.